PROAIR HFA
Clinical safety rating
cautionComprehensive clinical and safety monograph for PROAIR HFA (PROAIR HFA).
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
| Metabolism | Primarily metabolized by catechol-O-methyltransferase (COMT) and to a lesser extent by sulfation; not metabolized by CYP450 enzymes. |
| Excretion | Renal: approximately 72% as unchanged drug and metabolites; fecal: approximately 10%; biliary: minimal. |
| Half-life | Terminal elimination half-life: 3.8 to 5 hours; clinically, this supports a dosing interval of every 4-6 hours as needed for symptom relief. |
| Protein binding | Approximately 94% bound to human serum albumin. |
| Volume of Distribution | Vd: 1.9 to 2.7 L/kg; this large Vd indicates extensive distribution into tissues, including lung tissue. |
| Bioavailability | Inhalation: approximately 10-20% of the administered dose reaches the lungs; the remainder is swallowed and undergoes first-pass metabolism resulting in negligible oral bioavailability. |
| Onset of Action | Inhalation: 5 to 15 minutes. |
| Duration of Action | Inhalation: 3 to 6 hours; clinical note: duration may be shorter in patients with more severe airways obstruction. |
| Molecular Weight | 576.71 |
Two inhalations (90 mcg each) via oral inhalation every 4-6 hours as needed; for prevention of exercise-induced bronchospasm, two inhalations 15-30 minutes before exercise.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Children 4-11 years: Two inhalations (90 mcg each) via oral inhalation every 4-6 hours as needed; for exercise-induced bronchospasm, two inhalations 15-30 minutes before exercise. Children <4 years: Safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; use with caution due to potential for decreased renal function and increased sensitivity to beta-agonists. |
| 1st trimester | Limited data; use only if clearly needed. No evidence of teratogenicity in animal studies. |
| 2nd trimester | No known risk; monitor for maternal tachycardia and hypoglycemia. |
| 3rd trimester | May inhibit uterine contractions; avoid prolonged use near term. |
Clinical note
Comprehensive clinical and safety monograph for PROAIR HFA (PROAIR HFA).
| Placental transfer | Crosses placenta; fetal serum levels approximately 50% of maternal levels. |
| Breastfeeding | Excreted into breast milk in small amounts; unlikely to cause adverse effects in infant. Use caution due to potential for beta-adrenergic stimulation. |
| Lactation Rating | L2 (Safer in breastfeeding context) |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, albuterol sulfate caused fetal malformations (cleft palate, limb defects) at doses 0.4-1.2 times the maximum human daily inhalation dose. Risk cannot be ruled out; use only if potential benefit justifies potential risk. For trimester-specific risks: first trimester: potential for orofacial clefts and limb defects; second/third trimesters: risk of maternal tachycardia and hypoglycemia in neonate; labor inhibition near term; possible neonatal transient hypoglycemia. |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and serum potassium (risk of hypokalemia). In pregnancy, assess fetal heart rate patterns and uterine activity. Monitor for signs of preterm labor suppression. Assess maternal respiratory status and peak expiratory flow. In neonates, monitor for transient hypoglycemia, tachycardia, and jitteriness if used near delivery. |
| Fertility Effects | No human data on fertility. In animal studies, albuterol caused decreased fertility in rats at doses 50 times the maximum human daily inhalation dose. Effect on human fertility is unknown. |
■ FDA Black Box Warning
Not applicable; no black box warning.
| Serious Effects |
Hypersensitivity to albuterol or any componentCardiac tachyarrhythmias (e.g., atrial fibrillation with rapid ventricular rate)
| Precautions | Paradoxical bronchospasm may occur, Cardiovascular effects: increased heart rate, blood pressure, or ECG changes, Immediate hypersensitivity reactions, Potentially severe hypokalemia, May exacerbate diabetes and ketoacidosis |
| Food/Dietary | No significant food interactions. Avoid caffeine and stimulants as they may increase cardiovascular side effects (tachycardia, palpitations). No dietary restrictions required. |
| Clinical Pearls | Primarily a rescue inhaler for acute asthma exacerbations. Not for maintenance therapy. Shake well before each use. Prime with 3 test sprays when new or not used for >2 weeks. Use spacer device to improve lung deposition and reduce oropharyngeal side effects. Monitor for paradoxical bronchospasm. Tachycardia and hypokalemia can occur with overuse. Replace canister after 200 actuations. |
| Patient Advice | Use only as needed for shortness of breath, wheezing, or chest tightness. · Do not use more frequently than prescribed; overuse can lead to serious side effects. · Shake the inhaler vigorously for 5 seconds before each spray. · Prime the inhaler by releasing 3 test sprays into the air before first use or if not used for more than 2 weeks. · Use a spacer device if prescribed to improve medication delivery to the lungs. · Rinse mouth with water after each use to prevent thrush (oral fungal infection). · Seek immediate medical help if symptoms worsen or if you need more than 2 puffs per week for relief. · Store at room temperature away from moisture and heat; do not freeze. |
Loading safety data…